Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Cavuto

Adolescent Medicine Westfield, NJ Medical Doctor

NPI 1366483208 CMS profile 288973

532 E Broad St, Westfield, NJ 07090

Open in the dashboard

General payments

$4,631

216 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Cavuto of Westfield, NJ is reported in the CMS Open Payments database as having received $4,631 across 216 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Adolescent Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $528 29
2024 General $456 27
2023 General $431 29
2022 General $585 46
2021 General $552 40
2020 General $1,768 22
2019 General $311 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Cavuto
  • Adolescent Medicine median
  • Middle half of Adolescent Medicine
  • National median

In program year 2025, general payments to John Cavuto were reported at $528. Among 914 Adolescent Medicine profiles paid that year, the median was $100 and the middle half received between $40 and $207.

Show as a table
Year John Cavuto Adolescent Medicine median Middle half National median
2019 $311 $95 $36–$198 $163
2020 $1,768 $50 $23–$111 $114
2021 $552 $67 $27–$179 $132
2022 $585 $79 $29–$189 $149
2023 $431 $100 $39–$194 $160
2024 $456 $93 $38–$195 $164
2025 $528 $100 $40–$207 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $1,895 35 payments
  2. GlaxoSmithKline, LLC. $358 24 payments
  3. Cranial Technologies, Inc $323 22 payments
  4. Merck Sharp & Dohme Corporation $310 22 payments
  5. Supernus Pharmaceuticals, Inc. $284 21 payments
  6. Sanofi Pasteur Inc. $196 10 payments
  7. Corium, Inc. $192 13 payments
  8. Neos Therapeutics, LP $187 12 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $153 11 payments
  10. Genentech USA, Inc. $118 8 payments
  11. Other $615 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,131 214 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,500 2 payments
Products named General payments · program years 2019–2025
  1. TRUMENBA $1,809 29 payments
  2. BEXSERO $358 24 payments
  3. Doc Band $323 22 payments
  4. GARDASIL 9 $272 19 payments
  5. QELBREE $234 17 payments
  6. PEDIARIX $234 15 payments
  7. PREVNAR 13 $214 21 payments
  8. Azstarys $192 13 payments
  9. COTEMPLA XR-ODT $172 11 payments
  10. VAXELIS $169 12 payments
  11. Other $2,264 147 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

216 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adolescent Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record